Aisling Capital Management LP
Long book
$476.3M
Q1 2026
Positions
13
Top-10 weight
99%
concentration
Last quarter
+9.2%
SPY +14.8%
Turnover
14%
of book per quarter
Strategy in plain words
auto-generated from filingsAisling Capital Management LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $476.3M US long book across 13 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: BRIDGEBIO PHARMA INC, SYNDAX PHARMACEUTICALS INC, MONTE ROSA THERAPEUTICS INC, BICARA THERAPEUTICS INC, BRIDGEBIO ONCOLOGY THERAPEUT.
Over the last 9 quarters its long book ran on average 6pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-21.3%
Q2 2024
+2.7%
Q3 2024
-0.6%
Q4 2024
+13.6%
Q1 2025
+18.8%
Q2 2025
+26.0%
Q3 2025
+48.3%
Q4 2025
-2.4%
Q1 2026
+9.2%
Sector allocation
Healthcare 100%
Long book by quarter
What does Aisling Capital own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 5.1M | $378.0M | 79.4% | Held |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.3M | $30.8M | 6.5% | Held |
| GLUE MONTE ROSA THERAPEUTICS INC | Healthcare | 1.6M | $25.6M | 5.4% | +5.7% |
| BCAX BICARA THERAPEUTICS INC | Healthcare | 568.9K | $11.3M | 2.4% | Held |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | Healthcare | 1.0M | $9.1M | 1.9% | +80.3% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 77.0K | $3.8M | 0.8% | Held |
| BMEA BIOMEA FUSION INC | Healthcare | 2.0M | $3.1M | 0.7% | Held |
| EPRX EUPRAXIA PHARMACEUTICALS INC | Healthcare | 325.0K | $2.4M | 0.5% | New |
| URGN UROGEN PHARMA LTD | Healthcare | 108.0K | $1.9M | 0.4% | Held |
| ACRS ACLARIS THERAPEUTICS INC | Healthcare | 434.5K | $1.6M | 0.3% | Held |
| MRKR MARKER THERAPEUTICS INC | Healthcare | 325.4K | $423K | 0.1% | Held |
| OKUR ONKURE THERAPEUTICS INC-A | Healthcare | 88.6K | $367K | 0.1% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 5, 2026 | 13 | $476.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 10, 2026 | 13 | $478.9M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 12, 2025 | 14 | $456.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 13 | $359.7M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 13, 2025 | 13 | $288.5M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 12, 2025 | 15 | $281.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 16 | $261.1M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 8, 2024 | 15 | $231.1M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 16 | $295.5M | canonical | SEC ↗ |